Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vicriviroc/MK 2048

Drug Profile

Vicriviroc/MK 2048

Alternative Names: MK 2048/MK 4176; MK 2048/vicriviroc; MK 2048A IVR; MK 4176/MK 2048; VCV/MK 2048

Latest Information Update: 28 Jul 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Amides; Antiretrovirals; Benzyl compounds; Naphthyridines; Piperazines; Pyrazines; Pyridazines; Pyrimidines; Pyrimidinones; Pyrroles; Small molecules
  • Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Vaginal, Ring)
  • 17 Jul 2015 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for HIV infections (Prevention, In volunteers) in USA (NCT02419456)
  • 18 Jun 2015 Phase-I clinical trials in HIV infections (Prevention, In volunteers) in USA (Vaginal) (NCT02356302)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top